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Abstract
Endothelin-1 (ET-1) is a pivotal mediator of vasoconstriction and inflamma-
tion in congestive states such as heart failure (HF) and chronic kidney disease
(CKD). Whether peripheral venous congestion (VC) increases plasma ET-1 at
pressures commonly seen in HF and CKD patients is unknown. We seek to
characterize whether peripheral VC promotes time- and dose-dependent
increases in plasma ET-1 and whether these changes are sustained after decon-
gestion. We used a randomized, cross-over design in 20 healthy subjects (age
30  7 years). To experimentally model VC, venous pressure was increased to
either 15 or 30 mmHg (randomized at first visit) above baseline by inflating a
cuff around the subject’s dominant arm; the nondominant arm served as a
noncongested control. We measured plasma ET-1 at baseline, after 20, 60 and
120 min of VC, and finally at 180 min (60 min after cuff release and decon-
gestion). Plasma ET-1 progressively and significantly increased over 120 min
in the congested arm relative to the control arm and to baseline values. This
effect was dose-dependent: ET-1 increased by 45% and 100% at VC doses of
15 and 30 mmHg, respectively (P < 0.05), and declined after 60 min of
decongestion though remaining significantly elevated compared to baseline. In
summary, peripheral VC causes time- and dose-dependent increases in plasma
ET-1. Of note, the lower dose of 15 mmHg (more clinically relevant to HF
and CKD patients) was sufficient to raise ET-1. These findings support the
potentially contributory, not merely consequential, role of VC in the patho-
physiology of HF and CKD.
Introduction
Endothelin-1 (ET-1) is an important vasoactive peptide
primarily produced in vascular endothelial cells (ECs). In
humans, its vasoconstrictor actions predominate with
additional pro-inflammatory, pro-oxidant, thrombotic,
mitogenic, and proliferative properties. As such, it has
been implicated in the pathogenesis of congestive disease
states such as heart failure (HF) and chronic kidney
disease (CKD) (Komuro et al. 1988; Cowburn et al. 1999;
Teerlink 2005).
Venous congestion and elevated plasma ET-1 levels are
frequently present in advanced and acute HF and kidney
disease with a decline in levels with clinical improvement
(Rodeheffer et al. 1992; Kohan 1997; White et al. 2006).
While prognostic and pathophysiologic relevance of this
increase in ET-1 is widely accepted, causal mechanisms
remain the subject of intense investigation.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2017 | Vol. 5 | Iss. 6 | e13118
Page 1
Physiological Reports ISSN 2051-817X
We recently showed that plasma ET-1 concentration
and ET-1 expression in venous ECs acutely increase in
response to experimental severe venous congestion (VC)
(Colombo et al. 2014). However, in this model, the
increase in peripheral venous pressure (PVP) (which typi-
cally exceeds central venous pressure by 2–3 mmHg)
(Munis et al. 2001; Hadimioglu et al. 2006) was extreme
(30 mmHg above baseline levels) and short in duration
(75 min), thus not realistically mimicking the hemody-
namic conditions of peripheral congestion in HF and
CKD patients. It is, therefore, critical to understand if
lower levels of VC also lead to increased ET-1 levels and
if so how quickly these changes occur, and whether or
not they are sustained in the setting of decongestion.
To address these scientific questions, we designed this
study to test the hypothesis that acute experimental VC at
levels similar to those clinically observed in congestive
states is sufficient to cause a time- and dose-dependent
increase in local concentration of plasma ET-1.
Materials and Methods
We enrolled normotensive, nonsmoking subjects with no
history of chronic illness or chronic medication use. Sub-
jects had to abstain from alcohol consumption or exercise
for at least 24 h prior to each test. The protocol was
approved by the Institutional Review Board of Columbia
University. All subjects provided informed written con-
sent.
We used a randomized, cross-over design to study two
doses of experimental VC (15 or 30 mmHg, randomly
assigned at the first of two encounters). Encounters were
separated by at least 6 days.
After an overnight fast, subjects were placed in a quiet
room, in a supine position for 30 min prior to initiation
of the test. An 18-gauge angiocatheter was placed in the
antecubital or basilic vein of each arm. Local VC was then
applied at either 15 or 30 mmHg above baseline level by
inflating a cuff around the upper portion of the dominant
arm (test arm). During the test, a pressure transducer
(Agilent, Santa Clara, CA) was connected to the angio-
catheter of the test arm to monitor PVP. Blood was sam-
pled from the antecubital or basilic vein of the control
arm at baseline (time 0) and from the control and test
arms after 20, 60, and 120 min of VC and again at
180 min (i.e., 60 min after cuff release and decongestion).
Vital signs and peripheral arterial oximetry were mea-
sured at baseline and after 120 min of VC.
Plasma ET-1 was measured using a quantitative
immunoassay kit (R&D Systems, Minneapolis, MN).
Venous lactate was determined using an enzymatic colori-
metric method on the Cobas Integra 400 Plus Analyzer
(Roche Diagnostics, Indianapolis, IN). Results are
expressed as the mean of duplicate determinations and
values.
We used paired t-tests to examine whether ET-1 levels
differed by time and/or level of VC.
Results
Twenty subjects were studied. Nineteen completed the
two-encounter protocol. One subject was lost to follow
up after the first encounter. Thus, the 15 mmHg data set
includes 20 subjects, whereas the 30 mmHg data set
includes 19 subjects. No adverse events were observed.
Overall, study subjects were young and had a normal
body mass index, lipid profile, serum glucose, and renal
function (see Table 1).
PVP rose from 4  2 mmHg and 3  2 mmHg at
baseline to 19  2 mmHg (P < 0.0001) and
33  2 mmHg (P < 0.0001) at a VC dose of 15 and
30 mmHg, respectively.
Systolic blood pressure did not change in response to
VC when compared with baseline (113  9 vs.
113  8 mmHg and 114  6 vs. 117  9 mmHg at a
VC dose of 15 and 30 mmHg, respectively, all P = NS).
Diastolic BP also remained similar (72  6 vs.
73  8 mmHg and 71  6 vs. 76  8 mmHg at a VC
dose of 15 and 30 mmHg, respectively, all P = NS). Heart
rate was lower after 120 min of VC when compared to
baseline at a VC dose of 15 mmHg (65  8 vs.
59  7 bpm, P < 0.01), but not at a VC dose of
30 mmHg (64  9 vs. 60  6 bpm, P = NS). Peripheral
arterial oxygen saturation was 98  1% at baseline and
remained unchanged in response to both doses of VC.
In the congested arm, venous lactate was higher at
baseline than after 120 min of VC though this difference
was not significant (0.97  0.34 vs. 0.84  0.13 mmol/L
and 0.86  0.19 vs. 0.84  0.14 mmol/L, at a VC dose of
15 and 30 mmHg, respectively, all P = NS). However,
levels were higher in the congested arm when compared
to control arm at both VC doses after 120 min
Table 1. Subject characteristics (N = 20).
Variable Mean  SD
Age (years) 30  7
Gender (no. male/female) 19/1
Body mass index (kg/m2) 22.2  2.9
Total cholesterol (mg/dL) 148  26
Low-density cholesterol (mg/dL) 79  23
High-density cholesterol (mg/dL) 55  18
Triglycerides (mg/dL) 72  41
Blood glucose (mg/dL) 94  8
Serum creatinine (mg/dL) 0.86  0.13
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(0.84  0.13 vs. 0.74  0.13 mmol/L and 0.84  0.14 vs.
0.75  0.19 mmol/L, at 15 and 30 mmHg, respectively,
all P < 0.05). Of note, all venous lactate results (range
0.50–1.21 mmol/L) were within normal limits (normal
range: 0.56–2.22 mmol/L), and the lactate difference
between congested and control arm at 120 min was simi-
lar with both VC doses (0.09  0.09 and
0.09  0.82 mmol/L, at a VC dose of 15 and 30 mmHg,
respectively, P = NS).
Figure 1 shows plasma ET-1 levels at a VC dose of
15 mmHg (1A) and 30 mmHg (1B) as a function of time.
In the congested arm, both doses of VC were associated
with a time-dependent increase in plasma ET-1, starting
at 20 min, compared to baseline and control arm values.
In the control arm, plasma ET-1 increased significantly
compared to baseline, only at a dose of 30 mmHg and
after 60 min of VC. At both doses of VC, plasma ET-1
decreased following decongestion, but remained elevated
after 60 min compared to baseline.
Figure 2 compares the mean difference in plasma ET-1
between each time point and baseline values in the con-
gested arm for the two doses of VC. The increase in ET-1
was consistently higher at a VC dose of 30 mmHg than
15 mmHg, though this was only statistically significant
after 120 min of VC. The difference in plasma ET-1 con-
centration between the two dosages remained significant
after 60 min of decongestion.
Discussion
Experimental VC causes a time- and dose-dependent
increase of ET-1 with levels that decline, but remain ele-
vated after 1 hour of decongestion. We previously showed
that plasma ET-1 levels increase after 75 min of extreme
VC, 30 mmHg above baseline levels (Colombo et al.
2014). We now demonstrate for the first time that (1)
lower, more clinically relevant levels of peripheral VC are
sufficient to promote an acute increase in plasma ET-1,
(2) this increase is time dependent, and (3) plasma levels
decline but remain elevated after 1 hour of decongestion.
Venous congestion is typically considered a conse-
quence of HF and CKD. However, there is growing evi-
dence that congestion itself may drive the pathogenesis of
these chronic diseases as well. Recent work demonstrated
that peripheral venous distension causes a
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Figure 1. Plasma endothelin-1 time response to venous congestion (VC) at a dose of 15 mmHg (A) and 30 mmHg (B); 30 mmHg data at
180 min in the test arm are based on a sample of 18 subjects; 15 mmHg data at 60 min in the control arm are based on a sample of 19
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Figure 2. Plasma endothelin-1 changes from baseline according to
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sympathoexcitatory reflex leading to vasoconstriction and
increases in systemic blood pressure (Cui et al. 2012). In
our experimental model, clinically relevant levels of
peripheral VC are associated with a local increase in
plasma ET-1. Plasma ET-1 increases in patients with
symptomatic HF and CKD. In HF patients, plasma levels
rise to 2.1  1.0, 2.6  0.9, and 3.4  0.8 pg/mL with
increasing NYHA symptom class (I–III, respectively)
(Kinugawa et al. 2003), while in patients with proteinuric
CKD, the plasma levels of ET-1 increase to reported levels
of 3.6  0.5 pg/mL (Dhaun et al. 2013). Importantly,
these ET-1 levels are similar to the those observed in our
experimental model.
Interestingly, plasma ET-1 also increased significantly
in the control arm of the 30 mmHg group after 60 min
of VC. The reason for this increase is not clear. Spillover
from the test arm and systemic sympathoexcitatory reflex
(Cui et al. 2012) are potential contributors to this find-
ing.
Our current data do not fully elucidate the mechanisms
for the increase in plasma ET-1 in response to differing
doses of peripheral VC. This increase could be the result
of augmented ET-1 production or be due to diminished
ET-1 clearance. Prior work investigating elevated ET-1
levels in patients with congestive HF suggests that
increases in ET-1 are largely attributable to increased pep-
tide production. In fact, the clearance rate of ET-1 in
these patients was noted to be increased (Parker and
Thiessen 2004). Mechanistically, augmented production
of ET-1 secondary to venous distension is a plausible con-
tributor. A prior study suggests that biomechanical stress
in cultured endothelial cells upregulates the production of
ET-1 (Hasdai et al. 1997). Additional in vivo work in
humans demonstrated that local venous congestion leads
to differential expression of ET-1 in venous endothelial
cells (Colombo et al. 2014). Based on these prior results,
it is reasonable to hypothesize that a local increase in
endothelial ET-1 expression and production may, at least
in part, contribute to the observed increase in plasma
levels of ET-1 seen in this study.
It is important to note that tissue hypoxia may also
promote endothelial ET-1 production (Kourembanas
et al. 1991). This is an important consideration in the
current experimental model given the application of a
pressure cuff in the test arm that may partially decrease
arterial inflow in addition to venous outflow. Experimen-
tal VC did induce a marginal but significant dose-inde-
pendent increase in venous lactate in the congested arm
when compared with the control arm, while postconges-
tion levels did not differ from baseline values, as previ-
ously reported (Colombo et al. 2014). However, (1)
arterial oxygen saturation remained unchanged in
response to both doses of VC; (2) all lactate levels were
within normal limits; and, most importantly, (3) plasma
ET-1 increase was dependent on the VC dose while the
difference in venous lactate between test and control arm
at 120 min was the same with both doses of VC (i.e.,
dose-independent). Taken together these results suggest
that vascular stretch from VC rather than a marginal shift
to anaerobic metabolism was primarily responsible for the
observed increase in plasma ET-1.
Finally, plasma levels of ET-1 rapidly started to
decrease during decongestion. To date, there is no clinical
evidence that endothelin receptor antagonism leads to
improved clinical outcomes in patients with decompen-
sated HF undergoing concurrent decongestion with intra-
venous diuretics (McMurray et al. 2007). Results from
this study suggest the provocative concept that deconges-
tion may be sufficient in reducing the pathophysiologic
effects of ET-1 in severe congestive states, by decreasing
plasma levels of ET-1. Thus, endothelin receptor antago-
nism may be somehow redundant when coupled with
adequate venous decongestion in this patient population.
Several limitations of this study set the stage for future
work. First, women were not represented in our cohort of
subjects. This is an important consideration given poten-
tial gender differences in endothelin biology (Ergul et al.
1998). Second, in contrast to our previous model which
coupled blood and endothelial samplings, we did not pur-
sue endothelial collections in this study, as we considered
this approach (a total of five endothelial samplings per
encounter) too high risk for the development of throm-
bophlebitis. Third, as mentioned previously, cuff inflation
not only promoted VC but may have necessarily caused
(1) a reduction in arterial perfusion pressure by imping-
ing on the brachial artery and (2) hydrostatic pooling by
reducing venous flow. Interestingly, these features are typ-
ical of advanced HF where arterial blood pressure pro-
gressively declines and chronic venous insufficiency is
frequent (White and Ryjewski 2005), thus making our
model even more relevant from a pathophysiological
standpoint. Finally, we studied healthy subjects rather
than patients with HF and/or CKD. However, this pro-
vides a strong proof-of-principle for the concept of
hypervolemia as a fundamental stimulus for the patho-
physiology of HF and CKD without confounding bias
from comorbidities and/or medical therapies.
In conclusion, our present findings expand the concept
that VC may be a contributor to as well as a consequence
of the pathophysiology of congestive states such as HF
and CKD through a release of ET-1 that is time and dose
dependent in nature. Our results also suggest that decon-
gestion therapy and volume optimization may not only
relieve symptoms, but also contribute to reduce ET-1
mediated pathophysiological processes such as inflamma-
tion and vasoconstriction.
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